Osswald H - Search Results

1

Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis.

Winde G, Schmid KW, Brandt B, Müller O, Osswald H. Winde G, et al. Among authors: osswald h. Dis Colon Rectum. 1997 Oct;40(10):1156-68; discussion 1168-9. doi: 10.1007/BF02055161. Dis Colon Rectum. 1997. PMID: 9336110 Clinical Trial.

2

Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.

Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bünte H. Winde G, et al. Among authors: osswald h. Dis Colon Rectum. 1995 Aug;38(8):813-30. doi: 10.1007/BF02049838. Dis Colon Rectum. 1995. PMID: 7634976 Clinical Trial.

3

The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration.

Winde G, Gumbinger HG, Osswald H, Kemper F, Bünte H. Winde G, et al. Among authors: osswald h. Int J Colorectal Dis. 1993 Mar;8(1):13-7. doi: 10.1007/BF00341270. Int J Colorectal Dis. 1993. PMID: 8388011 Clinical Trial.

4

Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention.

Winde G, Lügering N, Glodny B, Schmid KW, Müller O, Senninger N, Osswald H. Winde G, et al. Among authors: osswald h. Cancer Lett. 1998 Dec 25;134(2):201-7. doi: 10.1016/s0304-3835(98)00254-7. Cancer Lett. 1998. PMID: 10025882

5

Influence of cisplatinum and 5-fluorouracil on the oral mucosa.

Zöller J, Flentje M, Born IA, Osswald H. Zöller J, et al. Among authors: osswald h. Eur J Cancer B Oral Oncol. 1994 May;30B(3):200-3. doi: 10.1016/0964-1955(94)90092-2. Eur J Cancer B Oral Oncol. 1994. PMID: 7920167

6

Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells.

Karl T, Seibert N, Stöhr M, Osswald H, Rösl F, Finzer P. Karl T, et al. Among authors: osswald h. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20. Cancer Lett. 2007. PMID: 16488075

7

[Effect of a cisplatin-5-fluorouracil combination chemotherapy on malignant transformation of the epithelium of mouth mucosa].

Zöller J, Maier H, Flentje M, Born IA, Osswald H. Zöller J, et al. Among authors: osswald h. HNO. 1994 May;42(5):257-63. HNO. 1994. PMID: 8050913 German.

8

Redifferentiation of oral dysplastic mucosa by the application of the antioxidants beta-carotene, alpha-tocopherol and vitamin C.

Barth TJ, Zöller J, Kübler A, Born IA, Osswald H. Barth TJ, et al. Among authors: osswald h. Int J Vitam Nutr Res. 1997;67(5):368-76. Int J Vitam Nutr Res. 1997. PMID: 9350480

9

Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210.

Osswald H, Frank N. Osswald H, et al. J Cancer Res Clin Oncol. 1990;116(5):448-52. doi: 10.1007/BF01612992. J Cancer Res Clin Oncol. 1990. PMID: 1699945

10

Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.

Efferth T, Klett T, Mattern J, Osswald H, Pommerenke EW, Stöhr M, Volm M. Efferth T, et al. Among authors: osswald h. Anticancer Res. 1991 May-Jun;11(3):1275-9. Anticancer Res. 1991. PMID: 1888160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

270 results

Search Page